Beo Therapeutics, Genbioma & Lactobio announced as 2022 Probiota Pioneers

The pioneering trio will be joining us at Probiota in Copenhagen next month, where there will be plenty of opportunity to meet them at the Pioneers Hub in the networking area at the event.

“The Pioneers are one of the highlights of Probiota and one that was sorely missed last year,”​ explains Will Chu, Science and Technology Editor at NutraIngredients.

“Beo Therapeutics, Genbioma and Lactobio represent the future of this sector and their presence in Copenhagen is warmly welcomed as they showcase innovative, cutting edge thinking fuelled by the desire to advance human health and wellbeing.”   ​

Beo Therapeutics​

The judges were impressed by Beo Therapeutics’​​ commitment to creating oral bacterial products that aims to counteract the effect of modern lifestyles and ageing on health

Founded in 2019, the firm are also looking into novel microbial treatments for arthritis and chronic kidney disease – two conditions linked to ageing and a western lifestyle that can be prevented.

“Of most interest to Probiota Pioneers are our probiotic ingredients for the ‘sports and recovery’ and ‘longevity and ageing’ that are ready for commercialisation,”​ adds the Zurich-based innovators.

“We intend to enter the market together with a partner that have established themselves on the market already and we would use the opportunity at Probiota Pioneers to connect with partners.”​

According to the Beo, the firm is built on a platform where they can identify bacteria that helps degrade and excrete toxic human metabolites via the gut.

The bacteria are all natural and no genetic engineering is employed. This enables the team to commercialise products under food-regulation as ingredients, food-supplements or medical foods. 

Genbioma​

The judges were also quick to commend the second of our Pioneers, in which Genbioma​ ​made a strong case as a leader in the management of hyperglycaemia-related conditions.

Also founded in 2019, Genbioma used its industrial know-how from probiotic animal feed and research on animal health, to advance its R&D on probiotics for food applications in human health.

“Our goal is to help manage diseases such as diabetes, lipid metabolism and obesity through the microbiome study,”​ the Spanish-based firm explains.

“We’ll validate long term effectiveness on the  prediabetic population (healthy people) first and secondly on diabetic type 2 patients. ​

“Thanks to their mechanism of action (Genbioma strain collection) and the preliminary preclinical results, the next generation of Premium Probiotics will aim to manage the lipid metabolism (cholesterol and obesity). ​

“Not only through probiotics but also symbiotics (combination of prebiotics and probiotics), which are IP protected.”​

Besides the scientific and industrial founder team, the firm is supported by private investors (Clave Capital), strategic partners from the pharmacy sector (CINFA) and animal health and nutrition (Pentabiol S.L.) as well as a research agreement with the Centre for Nutrition Research - University of Navarra.

Lactobio​

Lactobio​​ make up the last of this year’s trio with the judges homing in on the firm’s efforts to build a discovery and screening platform that identifies the best Lactic acid bacterial strains to target microbiome dysfunctions associated with skin and gut health problems.

In the process of developing topical microbiome, probiotic and postbiotic products, the team explains that they have isolated more than1000 new lactic acid bacteria.

Consequently, the Copenhagen-based firm have patented strains Lactobacillus plantarum LB244R​ and LB356R ​that have been selected due to their ability to balance the skin microbiome in respect to S. aureus​ and C. acnes ​and for its probiotic, health-promoting properties.

“In such a competitive market it means a lot for a start up like Lactobio to receive this form of recognition,”​ Lactobio CEO Søren Kjærulff explains.

”We are extremely pleased to receive this recognition. We always aim to develop innovative microbial solution and it means a lot to us that our work and passion is being noticed.”​

About Probiota​

Held on 23-25 February ​in Copenhagen, Probiota aims to bridge the gaps between cutting-edge science, business strategy, and key regulatory

developments in the microbiome, probiotic and prebiotic markets.

The three-day event will bring together CEOs, academics, and top researchers for networking opportunities, in addition to interactive presentations and debates in the fields of probiotics, prebiotics and the microbiome.

For more information and to register, please click HERE​​​​.